Arimidex
Anastrozole is an anti estrogenic drug developed for the treatment of advanced breast cancer in women. Specifically, this agent is the first in a newer class of third generation selective oral aromatase inhibitors. It acts by blocking the enzyme aromatase, subsequently blocking the production of estrogen in the body. Since many forms of breast cancer cells are stimulated by estrogen, reducing levels of this hormone in the body may retard the progression of the disease.
read more...Aromasin
Exemestane is a steroidal suicide aromatase inhibitor. It isvery similar in structure and action to formestane, although it is significantly more potent in comparison. As a class of drugs, aromatase inhibitors offer an anti estrogenic effect by blocking the enzyme responsible for synthesizing estrogens. Exemestane is approved by the FDA for the treatment of breast cancer in women, specifically in post menopausal patients whose cancer has progressed following therapy with tamoxifen (nolvadex).
read more...Clomid
Clomiphene citrate is an anti estrogenic drug that is prescribed to women to treat anovulatory infertility (inability to ovulate). In clinical medicine it is specifically referred to as a nonsteroidal ovulatory stimulant. The drug works by interacting with estrogen receptors, often in an antagonistic manner, in various tissues of the body including the hypothalamus, pituitary, ovary, endometrial, vagina, and cervix.
read more...Cytadren
Aminoglutethimide is mainly identified as an inhibitor of adrenocortical steroid synthesis. Its primary function is to block the conversion of cholesterol to pregnenolone, which is required for the biosynthesis of adrenal glucocorticoids, mineral corticoids, estrogens, and androgens.
read more...Evista
Raloxifene hydrochloride is a second generation selective estrogen receptor modulator (SERM) of the benzothiophene family. This drug is similar in its effects to the drug tamoxifen (nolvadex), exhibiting estrogen receptor antagonist properties in some tissues while acting as an estrogen receptor agonist in others. The main point of variation between the two drugs is their tissue selectivity. While raloxifene hydrochloride is a strong anti-estrogen in breat and uterine tissues, it appears to be estrogenic in bone.
read more...Fareston
Toremifene citrate is an anti-estrogenic drug, specifically classified as a selective estrogen receptor modulator (SERM) with mixed agonist and antagonist properties. It is a non steroidal triphenylethylene derivative, similar in structure to both the drugs nolvadex and clomid. Toremifen citrate is used for the treatment of breast cancer in postmenopausal women with the estrogen receptor positive or estrogenic receptor unknown tumors.
read more...Faslodex
Fulvestrant is a highly selective estrogen receptor antagonist. It exerts its action in the body not by targeting the production of estrogen, but by preventing it from exerting activity on the body. It does this by binding available estrogen receptors in a competitive manner, making them unavailable for circulating estrogens. This mode of action is very similar to Nolvadex and Clomid, although unlike these two agent fulvestrant does not have mixed agonist/antagonist properties.
read more...Femara
Letrozole is a non steroidal selective third generation aromatse inhibitor. The structure and activity of this compound are very similar to that of Arimidex, and is prescribed for similar medical reasons. More specifically, United States prescribing guidelines for leptosome recommend it to be used for the treatment of postmenopausal women with estrogen receptor positive or estrogen receptor unkown brest cancer.
read more...Nolvadex
Tamoxifen citrate is a non steroidal anti estrogenic drug, used widely in clinical medicine. It is specifically a selective estrogen receptor modulator of the triphenylethylene family, and posses both estrogen agonist and antagonist properties. As such, it may act as an estrogen in some tissues while acting as an anti-estrogen in others. In breast tissue the drug is a strong anti estrogen and as a result is commonly used in the treatment of estrogen related breast cancer in women.
read more...Teslac
Testolactone is a first generation non selective steroidal aromatase inhibitor, used clinically to treat estrogen dependant breast cancer. Its exact mode of funciton is unkown, but it is believed to inhibit the aromatase enzyme in a noncompetitive and irreversible manner. If so, this would be an activity that is very similar to that of Lentaron. This might also explain why cessation of the drug does not provide an immediate restoration of normal estrogen production.
read more...